IGC PHARMA INC (IGC)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.30-0.17%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IGC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 1.2 | — | 1.3 | 1.3 | 0.9 | 0.4 | 0.9 | 4.1 | 5.1 | 2.2 | 0.6 | 6.4 | 7.7 | 2.3 | 8.0 | 8.0 | 4.2 |
| Total Revenues | 1.2 | — | 1.3 | 1.3 | 0.9 | 0.4 | 0.9 | 4.1 | 5.1 | 2.2 | 0.6 | 6.4 | 7.7 | 2.3 | 8.0 | 8.0 | 4.2 |
| Cost of Revenues | 1.0 | — | 0.7 | 0.6 | 0.5 | 0.2 | 0.8 | 4.0 | 5.0 | 2.1 | 0.4 | 5.5 | 7.1 | 1.9 | 6.5 | 6.5 | 4.8 |
| Gross Profit | 0.2 | — | 0.6 | 0.7 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 5.6 | — | 4.4 | 6.8 | 8.6 | 13.3 | 7.9 | 6.0 | 3.5 | 1.7 | 2.3 | 2.7 | 4.1 | 2.2 | 3.0 | 3.0 | 4.7 |
| R&D Expenses | 5.5 | — | 3.7 | 3.8 | 3.5 | 2.3 | 0.9 | 1.0 | 1.3 | — | — | — | — | — | — | — | — |
| Operating Income | (11.0) | — | (7.4) | (9.8) | (11.6) | (15.4) | (8.7) | (6.9) | (4.6) | (1.8) | (2.1) | (2.9) | (4.3) | (2.5) | (2.5) | (2.5) | (7.5) |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | 0.0 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 1.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.7 |
| Asset Writedown | — | — | 0.2 | 3.4 | 0.0 | 0.8 | 0.0 | — | — | — | — | — | — | — | — | 0.3 | 2.2 |
| EBT, Incl. Unusual Items | (9.0) | — | (7.1) | (13.0) | (11.5) | (15.0) | (8.8) | (7.3) | (4.1) | (1.8) | (1.8) | (2.8) | (4.7) | (3.0) | (2.6) | (2.6) | (7.7) |
| Income Tax Expense | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.4) | (0.4) | 0.2 |
| Net Income | |||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | (0.0) | (0.1) | (0.0) | 0.0 | 0.0 | 0.1 |
| Net Income | (9.0) | — | (7.1) | (13.0) | (11.5) | (15.0) | (8.8) | (7.3) | (4.1) | (1.8) | (1.9) | (2.8) | (4.6) | (3.0) | (2.3) | (2.3) | (7.8) |
| Per Share | |||||||||||||||||
| Basic EPS | (0.09) | — | (0.09) | — | — | — | — | — | — | — | (0.07) | (0.17) | (0.31) | (0.37) | (0.32) | (0.32) | (2.66) |
| Diluted EPS | (0.09) | — | (0.09) | — | — | — | — | — | — | — | (0.07) | (0.17) | (0.31) | (0.37) | (0.32) | (0.32) | (2.66) |
| Revenue per Share | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 100.3 | — | 76.5 | 58.8 | 52.6 | 50.0 | 42.0 | 39.5 | 35.4 | 27.9 | 25.7 | 16.4 | 14.8 | 8.2 | 7.0 | 7.0 | 2.9 |
| Diluted Weighted Avg Shares | 100.3 | — | 76.5 | — | — | — | — | — | — | — | 25.7 | 16.4 | 14.8 | 8.2 | 7.0 | 7.0 | 2.9 |
| Supplemental | |||||||||||||||||
| EBITDA | — | — | (6.8) | (9.2) | (10.9) | (14.8) | (8.2) | (6.7) | (4.6) | (1.8) | (1.7) | (2.2) | (3.6) | (1.8) | (1.8) | (1.8) | (6.5) |
| EBIT | (11.0) | — | (7.4) | (9.8) | (11.6) | (15.4) | (8.7) | (6.9) | (4.6) | (1.8) | (2.1) | (2.9) | (4.3) | (2.5) | (2.5) | (2.5) | (7.5) |
| Effective Tax Rate | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | 0.0% | -0.8% | -0.0% | -0.1% | 0.0% | 13.9% | 13.9% | -2.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.